TY - JOUR
T1 - Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
AU - Stams, Wendy A G
AU - den Boer, Monique L
AU - Holleman, Amy
AU - Appel, Inge M
AU - Beverloo, H Berna
AU - van Wering, Elisabeth R
AU - Janka-Schaub, Gritta E
AU - Evans, William E
AU - Pieters, Rob
PY - 2005/6/1
Y1 - 2005/6/1
N2 - Resistance to L-asparaginase in leukemic cells may be caused by an elevated cellular expression of asparagine synthetase (AS). Previously, we reported that high AS expression did not correlate to L-asparaginase resistance in TEL-AML1-positive B-lineage acute lymphoblastic leukemia (ALL). In the present study we confirmed this finding in TEL-AML1-positive patients (n = 28) using microarrays. In contrast, 35 L-asparaginase-resistant TEL-AML1-negative B-lineage ALL patients had a significant 3.5-fold higher AS expression than 43 sensitive patients (P < .001). Using real-time quantitative polymerase chain reaction (RTQ-PCR), this finding was confirmed in an independent group of 39 TEL-AML1-negative B-lineage ALL patients (P = .03). High expression of AS was associated with poor prognosis (4-year probability of disease-free survival [pDFS] 58% +/- 11%) compared with low expression (4-year pDFS 83% +/- 7%; P = .009). We conclude that resistance to l-asparaginase and relapse risk are associated with high expression of AS in TEL-AML1-negative but not TEL-AML1-positive B-lineage ALL.
AB - Resistance to L-asparaginase in leukemic cells may be caused by an elevated cellular expression of asparagine synthetase (AS). Previously, we reported that high AS expression did not correlate to L-asparaginase resistance in TEL-AML1-positive B-lineage acute lymphoblastic leukemia (ALL). In the present study we confirmed this finding in TEL-AML1-positive patients (n = 28) using microarrays. In contrast, 35 L-asparaginase-resistant TEL-AML1-negative B-lineage ALL patients had a significant 3.5-fold higher AS expression than 43 sensitive patients (P < .001). Using real-time quantitative polymerase chain reaction (RTQ-PCR), this finding was confirmed in an independent group of 39 TEL-AML1-negative B-lineage ALL patients (P = .03). High expression of AS was associated with poor prognosis (4-year probability of disease-free survival [pDFS] 58% +/- 11%) compared with low expression (4-year pDFS 83% +/- 7%; P = .009). We conclude that resistance to l-asparaginase and relapse risk are associated with high expression of AS in TEL-AML1-negative but not TEL-AML1-positive B-lineage ALL.
KW - Asparaginase/therapeutic use
KW - Aspartate-Ammonia Ligase/analysis
KW - Burkitt Lymphoma/drug therapy
KW - Child
KW - Core Binding Factor Alpha 2 Subunit
KW - Disease-Free Survival
KW - Drug Resistance, Neoplasm
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Oligonucleotide Array Sequence Analysis
KW - Oncogene Proteins, Fusion/analysis
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
KW - Prognosis
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=19344377657&partnerID=8YFLogxK
U2 - 10.1182/blood-2004-10-3892
DO - 10.1182/blood-2004-10-3892
M3 - Article
C2 - 15718422
SN - 0006-4971
VL - 105
SP - 4223
EP - 4225
JO - Blood
JF - Blood
IS - 11
ER -